HURA 424B5 SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

HURA ▲ +29.59% at T+20d

SHORT call ✗ call lost -29.59% · α vs SPY -22.02% · entry $1.96 → $2.54

Next anchor: T+60d in 23d

Last close $2.05 (close Jun 8) · -4.34% from $1.96 entry (call sign-flipped)

Entry anchored
Apr 8, 03:59 PM ET
via Databento tick

T+1d

+15.82%

call -15.82% · α -15.88%

$2.27

settled 2mo ago

T+5d

+51.02%

call -51.02% · α -47.83%

$2.96

settled 8w ago

T+20d

+29.59%

call -29.59% · α -22.02%

$2.54

settled 5w ago

T+60d

—

call — · α —

—

in 23d

Price Chart

Loading chart...

Executive Summary

TuHURA Biosciences is conducting an at-the-market (ATM) offering of up to $50 million in common stock, following a recent $12.6 million private placement. The company reported its 2025 financial results just one week prior, indicating a need for capital. The offering will dilute new investors by $1.25 per share and is being used for general corporate purposes.

Actionable Insight

Traders should monitor for immediate downward pressure on HURA stock price due to the ATM offering, especially given the recent earnings release. The dilution of $1.25 per share represents a significant immediate loss for new investors. Consider that management may be taking advantage of a temporary price spike following the Kineta merger and Phase 3 trial initiation to raise capital.

Key Facts

ATM offering of up to $50 million in common stock priced at market rates
Last reported stock price was $1.79 per share on March 31, 2026
Recent $12.6 million private placement completed in June 2025
Company reported 2025 financial results on April 1, 2026, just one week before this filing
New investors will experience $1.25 per share dilution based on $1.79 offering price
Proceeds to be used for working capital and general corporate purposes

Financial Impact

Up to $50 million in equity dilution with 3% underwriting commission

dilutionequitycash

Risk Factors

Significant immediate dilution for new investors ($1.25 per share)
ATM offering structure allows company to sell shares opportunistically at market highs
Proceeds are for general corporate purposes with no specific allocation
Recent capital raise ($12.6M private placement) suggests ongoing funding needs

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

Document	Accession Number
424B5 Filing (Primary)	0001193125-26-147748
Document: 0001193125-26-147748-index-headers.html	0001193125-26-147748
Document: 0001193125-26-147748-index.html	0001193125-26-147748
Document: 0001193125-26-147748.txt	0001193125-26-147748

6 reports for HURA

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for HURA — sortable, filterable
	Type				Now
May 29, 2026 11d ago	8-K NEUTRAL ★ 4/10	$2.24 $1.97	▼ −12.28%	▼ −9.53%	$2.05 (−8.71%)
May 15, 2026 25d ago	8-K NEUTRAL ★ 4/10	$2.55 $2.45	▼ −3.92%	▼ −5.54%	$2.05 (−19.80%)
Apr 22, 2026 6w ago	8-K MIXED ★ 7/10	$2.68 $2.15	▼ −19.96%	▼ −20.02%	$2.05 (−23.69%)
Apr 8, 2026 8w ago	424B5 BEARISH ★ 7/10	$1.96 $2.96	▼ −51.02%	▼ −47.83%	$2.05 (−4.34%)
Apr 8, 2026 8w ago	8-K NEUTRAL ★ 5/10	$1.96 $2.96	▲ +51.02%	▲ +47.83%	$2.05 (+4.34%)
Apr 1, 2026 9w ago	8-K BEARISH ★ 7/10	$1.62 $1.96	▼ −20.99%	▼ −17.22%	$2.05 (−26.23%)

US Market Status

Market Closed — Opens in 6h 51m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access